Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05847413 · ClinicalTrials.gov registry record · Early Phase 1
Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D
A Early Phase 1 study, sponsored by Benaroya Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT05847413: Completed Early Phase 1 study, sponsored by Benaroya Research Institute.
NCT05847413 is a Early Phase 1 study that has completed, run by Benaroya Research Institute. The registered enrollment target is 10 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05847413, a Early Phase 1 study, has completed, sponsored by Benaroya Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether verapamil can transiently improve beta cell function in those who do or do not secrete proinsulin and little/no C-peptide.
Interventions
- DRUG Verapamil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-05-30 |
| Est. Completion | 2021-12-10 |
| Phase | Early Phase 1 |
What the finished NCT05847413 record still lists
NCT05847413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which Verapamil is the first listed.
NCT05847413 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05847413 about?
NCT05847413 is a clinical study titled "Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D". The purpose of this study is to determine whether verapamil can transiently improve beta cell function in those who do or do not secrete proinsulin and little/no C-peptide.
What is the current status of trial NCT05847413?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2020-05-30. Estimated completion is 2021-12-10.
What interventions are being tested in trial NCT05847413?
The interventions under investigation include: Verapamil (DRUG).
Who is sponsoring clinical trial NCT05847413?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05847413's enrollment target sits among peer trials
10 1629th of 2000 higher than 256 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI